These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 28233269

  • 21. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
    [Abstract] [Full Text] [Related]

  • 22. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [Abstract] [Full Text] [Related]

  • 23. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
    [Abstract] [Full Text] [Related]

  • 24. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.
    Schmitz G, Orsó E.
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):21-5. PubMed ID: 25708587
    [Abstract] [Full Text] [Related]

  • 25. Hyperlipoproteinemia(a): clinical significance and treatment options.
    Berthold HK, Gouni-Berthold I.
    Atheroscler Suppl; 2013 Jan; 14(1):1-5. PubMed ID: 23357133
    [Abstract] [Full Text] [Related]

  • 26. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
    Sampietro T, Sbrana F, Bigazzi F, Ripoli A, Dal Pino B, Pasanisi EM, Petersen C, Coceani M, Luciani R, Pianelli M.
    Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
    [Abstract] [Full Text] [Related]

  • 27. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study.
    Klingel R, Heibges A, Fassbender C.
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):46-50. PubMed ID: 25644612
    [Abstract] [Full Text] [Related]

  • 28. Current standards in diagnosis and therapy of hyperlipoproteinemia.
    Fischer S, Schatz U, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):15-8. PubMed ID: 23357135
    [Abstract] [Full Text] [Related]

  • 29. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
    [Abstract] [Full Text] [Related]

  • 30. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ, Pottle A, Pennell DJ, Barbir MS.
    Atheroscler Suppl; 2015 May; 18():103-8. PubMed ID: 25936312
    [Abstract] [Full Text] [Related]

  • 31. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Scientific Board of GLAR for the German Apheresis Working Group.
    Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
    [Abstract] [Full Text] [Related]

  • 32. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
    Tselmin S, Müller G, Schatz U, Julius U, Bornstein SR, Hohenstein B.
    Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840
    [Abstract] [Full Text] [Related]

  • 33. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM.
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [Abstract] [Full Text] [Related]

  • 34. Lipoprotein apheresis: state of the art and novelties.
    Stefanutti C, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):19-27. PubMed ID: 23357136
    [Abstract] [Full Text] [Related]

  • 35. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease.
    Thompson GR.
    Atheroscler Suppl; 2013 Jan; 14(1):67-70. PubMed ID: 23357143
    [Abstract] [Full Text] [Related]

  • 36. Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity?
    Berthold HK, Descamps OS, Gouni-Berthold I.
    Eur J Clin Invest; 2013 Jan; 43(1):108-12. PubMed ID: 23190253
    [No Abstract] [Full Text] [Related]

  • 37. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
    Klingel R, Heigl F, Schettler V, Roeseler E, Grützmacher P, Hohenstein B, Vogt A, Fassbender C, Heibges A, Julius U.
    Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
    [Abstract] [Full Text] [Related]

  • 38. [Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].
    Schettler VJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, Deutsche Gesellschaft für Nephrologie (DGfN), Verband Deutsche Nierenzentren (DN).
    Internist (Berl); 2016 May; 57(5):511-6. PubMed ID: 27118008
    [No Abstract] [Full Text] [Related]

  • 39. Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia.
    Pokrovsky SN, Afanasieva OI, Ezhov MV.
    Curr Atheroscler Rep; 2020 Sep 18; 22(11):68. PubMed ID: 32945973
    [Abstract] [Full Text] [Related]

  • 40. Lipoprotein(a)-apheresis in the light of new drug developments.
    Vogt A.
    Atheroscler Suppl; 2017 Nov 18; 30():38-43. PubMed ID: 29096859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.